January 19, 2023BMC Nephrology45 citationsOpen Access
Clinical impact of suboptimal RAASi therapy following an episode of hyperkalemia
Structured PICO
Does RAASi discontinuation or down-titration increase the risk of cardiorenal events in patients following an episode of hyperkalemia?
P
Population
Patients with an episode of hyperkalemia on RAASi therapy
I
Intervention
RAASi discontinuation or down-titration
C
Comparator
Maintained or up-titrated RAASi
O
Outcome
Cardiorenal eventscomposite
Discontinuing or down-titrating RAAS inhibitors after a hyperkalemia episode is associated with worse cardiorenal outcomes compared to maintaining or up-titrating the therapy.
Abstract
HK-related RAASi discontinuation or down-titration was associated with higher risk of cardiorenal events versus maintained or up-titrated RAASi.